Viracta Therapeutics

37 articles with Viracta Therapeutics

• Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma

  6/1/2021

  Now open for enrollment, NAVAL-1 is a multicenter basket trial with an adaptive Simon 2-stage design

• Viracta Therapeutics to Host Key Opinion Leader Webinar

  5/18/2021

  Virtual KOL event to focus on the unmet medical need in relapsed/refractory EBV-positive lymphoma and the design of NAVAL-1, a global pivotal trial Event to take place on Thursday, May 20th at 2:00 PM ET

• Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

  4/8/2021

  Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20th Annual Needham Virtual Healthcare Conference taking place April 12-15, 2021

• Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

  3/11/2021

  Viracta  Therapeutics, Inc.  (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston , President and Chief Executive Officer of Viracta will present at the Oppenheimer 31 st Annual Healthcare Conference taking place virtually from March 16-18, 2021

• Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team

  3/4/2021

  Viracta  Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments of Drs. Stephen Rubino and Barry J. Simon to the Board of Directors

• Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference

  3/3/2021

  Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life Sciences Conference, being held March 9-10 , 2021.

• Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

  2/16/2021

  Viracta  Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance

• Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

  12/7/2020

  Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas.

• Viracta Therapeutics to Present at the Solebury Trout Fall Private Company Showcase 2020

  10/8/2020

    Viracta  Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston , MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the Solebury Trout Fall Private Company Showcase on Thursday, October 15, 2020 at 1:00 pm ET

• Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD, FACP as Chairman of the Board of Directors

  9/14/2020

  Viracta Therapeutics, Inc. ("Viracta" or the "Company"), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Roger J. Pomerantz, MD, FACP, as Chairman of its Board of Directors (the "Board")

• Viracta Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/9/2020

  Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference

• Viracta Announces the Appointment of Mark A. McCamish, MD, PhD as Strategic Advisor

  7/20/2020

  Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Mark A. McCamish , MD, PhD, has joined Viracta as a Strategic Advisor to the Company. Dr. McCamish will provide strategic, financial and operational guidance to the Viracta leadership team as the Com

• Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD to its Board of Directors

  7/14/2020

  Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Roger J. Pomerantz , MD, FACP, has been appointed to its Board of Directors. Dr. Pomerantz is currently the President, Chief Executive Officer and Chairman of the Board of Directors of ContraFect Corporation and brings

• Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering its Combination Product Candidate for the Treatment of Viral or Virally-Induced Conditions

  7/9/2020

  Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 15/959,482. T

• Viracta Therapeutics Announces Orphan Drug Designation Granted for the Treatment of T-cell Lymphoma

  6/24/2020

  Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that its Phase 2 all-oral combination product of nanatinostat and valganciclovir has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma. 

• Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma

  5/28/2020

  Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that it will host a key opinion leader (KOL) call discussing the treatment of Epstein-Barr virus (EBV)-associated lymphoma on Friday, June 5th at 12 P.M. Eastern Time.

• Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas

  4/8/2020

  Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that the Company recently held a collaborative and productive guidance (Type C) Meeting with the United States Food and Drug Administration (FDA). The Type C Meeting was held on March 31, 2020 regarding the

• Viracta Announces Appointment of Lisa Rojkjaer, MD, as Chief Medical Officer

  3/25/2020

  Viracta Therapeutics, Inc. announced the appointment of Lisa Rojkjaer, MD, as Chief Medical Officer, effective May 1, 2020.

• Viracta's Precision Oncology Research in EBV+ Cancers Highlighted at 16th Annual UCSD Moores Cancer Center Symposium

  2/18/2020

  Viracta Therapeutics, Inc. announced that Ivor Royston, M.D., the Company's President and CEO, will present an overview of Viracta's approach in treating patients with Epstein-Barr Virus -associated malignancies and data from the ongoing Phase 2 clinical trial in lymphoma.

• Viracta Therapeutics to Present at the 2020 BIO CEO & Investor Conference

  2/4/2020

  Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that Dan Chevallard, Chief Financial Officer of Viracta, will present a company overview at the 2020 BIO CEO and Investor Conference on Tuesday, February 11, 2020 at 2:30 pm ET in New York, NY.